Common Stock

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

	Washington			
STATEMENT	OF CHANGES I	N BENEFICIAL	OWNERSHIP	

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response

By 10X

Fund, LP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

or Section 30(h) of the Investment Company Act of 1940 5. Relationship of Reporting Person(s) to Issuer 2. Issuer Name and Ticker or Trading Symbol 1. Name and Address of Reporting Person (Check all applicable) PRO PHARMACEUTICALS INC [PRWP] CZIRR JAMES C 10% Owner Director Officer (give title Other (specify 3. Date of Earliest Transaction (Month/Day/Year) below) helow) (First) (Middle) (Last) 12/31/2009 425 JANISH DR 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) Line) 83864 **SANDPOINT** ID X Form filed by One Reporting Person Form filed by More than One Reporting Person (Citv) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2A. Deemed 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 6. Ownership Form: Direct 1. Title of Security (Instr. 3) 2. Transaction 7. Nature of **Execution Date** Indirect Securities (Month/Day/Year) Beneficial if any Code (Instr. Beneficially (D) or Indirect (Month/Day/Year) 8) Owned Following Ownership (Instr. 4) Reported

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

12/31/2009

Code ν (A) or (D)

Price

\$0.28(1)

Amount

260,027

Transaction(s)

(Instr. 3 and 4)

680,831

(e.g., puts, cans, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Series B-2 Convertible Preferred Stock	\$0.5	01/29/2010		P		162,500		(2)	(2)	Common Stock	650,000	\$2 ⁽³⁾	1,492,500	I	By 10X Fund, LP ⁽⁴⁾ (5)(6)
Series A-1 Warrant (right to buy)	\$0.5	01/29/2010		P		1		01/29/2010	01/29/2015	Common Stock	325,000	\$0 ⁽³⁾	8	I	By 10X Fund, LP ⁽⁴⁾ (5)(6)
Series A-2 Warrant (right to buy)	\$0.5	01/29/2010		P		1		01/29/2010	01/29/2015	Common Stock	325,000	\$0 ⁽³⁾	8	I	By 10X Fund, LP ⁽⁴⁾ (5)(6)
Series B Warrant (right to buy)	\$0.5	01/29/2010		P		1		01/29/2010	01/29/2015	Common Stock	1,300,000	\$0 ⁽³⁾	8	I	By 10X Fund, LP ⁽⁴⁾ (5)(6)
Option (right to buy)	\$0.3	02/01/2010		A		500,000		02/01/2010	02/01/2015	Common Stock	500,000	\$0	500,000	D	
Option (right to buy)	\$0.3	02/01/2010		A		500,000		(7)	02/01/2015	Common Stock	500,000	\$0	1,000,000	D	

Explanation of Responses:

- 1. On December 31, 2009, 10X Fund, L.P. received 260,027 shares of Common Stock of the Issuer in satisfaction of dividends on shares of Series B-1 and B-2 Convertible Preferred Stock owned by 10X Fund, L.P. Dividends on the Preferred Stock are payable in shares of the Issuer's Common Stock valued at \$0.50 per share, with regard to the actual market price of the Common Stock at the time of issuance. The market value of the Common Stock at the time of its issuance was less than \$0.50 per share
- 2. Each share of Series B-2 Convertible Preferred Stock is convertible into four shares of Issuer's common stock at a conversion price of \$0.50 per share (subject to customary anti-dilution protection adjustments) at the option of (a) the holder, at any time and (b) Issuer, at any time after December 8, 2010 (and upon 10 days notice) if the Issuer's common stock is quoted at or above \$1.50 per share for 15 consecutive trading days and an effective registration statement regarding the underlying shares of Issuer's common stock is in effect (subject to certain monthly volume limits). The shares of Series B-2 Convertible Preferred Stock do not
- 3. On January 29, 2010, 10X Fund, L.P. purchased (a) 162,500 shares of Series B-2 Preferred Stock, (b) one Class A-1 Warrant to purchase 325,000 shares of Common Stock for \$0.50 per share, (c) one Class A-2 Warrant to purchase 325,000 shares of Common Stock for \$0.50 per share, and (d) one Class B Warrant to purchase 1,300,000 shares of Common Stock for \$0.50 per share, for aggregate consideration of \$325,000.
- 4. Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., such portion being equal to 10X Capital Management, LLC's (a) 20% interest in the profits of 10X Fund, L.P., (b) interest in any securities which are used to pay a 2% annual management fee to 10X Capital Management, LLC, and (c) interest in one-half of the Class B Warrants acquired by 10X Fund, L.P. in all closings other than the initial closing held on February 12, 2009, less one Class B Warrant which 10X Capital Management, LLC has committed to reallocate to investors in all prior closings until each such investor has one (1) additional Class B Warrant for each dollar invested
- 5. Any such deemed indirect beneficial ownership may also be reduced by Mr. Czirr's proportional ownership in 10X Capital Management, LLC. Mr. Czirr disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- 6. Excludes (i) up to 607,500 shares of Series B-2 Preferred Stock convertible into 2,430,000 shares of Common Stock; (ii) Class A-1 Warrants exercisable to purchase up to 1,215,000 shares of Common Stock; (iii) Class A-2 Warrants exercisable to purchase up to 1,215,000 shares of Common Stock; and (iv) Class B Warrants exercisable to purchase up to 4,860,000 shares of Common Stock that 10X Fund, L.P. may purchase from Issuer within 60 days of the date hereof pursuant to a Securities Purchase Agreement dated February 12, 2009, as amended on August 11, 2009, between Issuer and 10X Fund, L.P.
- 7. The options vest in four equal parts quarterly over one year from the date of the option grant.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.